B. anthracis Real-time PCR Assay
Centers for Disease Control and Prevention · Decision date Oct 7, 2026
What did the FDA decide?
FDA's 510(k) database records K262368, a traditional premarket notification for the B. anthracis Real-time PCR Assay, submitted by the Centers for Disease Control and Prevention in Atlanta. The device falls under regulation number 866.3045, classification product code NHT, and the Microbiology review panel. FDA received the submission on 07/10/2026 and issued a decision on 10/07/2026.
The recorded decision is Substantially Equivalent (SESE), which for a 510(k) means clearance to market, not premarket approval. The page also notes the submission was not reviewed by a third party, is not a combination product, and that a Predetermined Change Control Plan was authorized. The public record does not describe the assay's components, intended use, performance data or the contents of the authorized change control plan; those details would require the underlying FDA review documents.
The record does not state whether this submission is an original or a subsequent 510(k) for the same device name, so its relationship to any earlier clearance remains unknown from this page alone.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Microbiology
- Decision date
- Oct 7, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K262368
- Regulatory pathway
- 510(k) premarket notification
- Product code
- NHT
- Decision code
- SESE
- Decision date
- Oct 7, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Assay, Nucleic Acid Amplification, Bacillus Anthracis.
- Product code
- NHT
- FDA device class
- 2
FDA decision timeline
K262368 received
Application receipt date recorded by FDA.
K262368 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
No additional submissions with a verified PMA or product-code relationship are linked here.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Centers for Disease Control and Prevention
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Atlanta, GA
Sources and methodology
- Original FDA record: K262368
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records